2-deoxy-2-phthalimido-D-glucopyranose | 31505-45-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-deoxy-2-phthalimido-D-glucopyranose
• 英文别名: 2-phthalimido-2-deoxy-α,β-D-glucopyranoside；2-phthalimdo-2-deoxy-D-glucopyranose；N-phthalimido-D-glucosamine；2-deoxy-2-N-phthalamido-β-D-glucopyranoside；N,N-phthaloyl-D-glucosamine；2-deoxy-2-phthalimido-D-glucose；2-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]isoindole-1,3-dione
• CAS: 31505-45-0
• 化学式: C₁₄H₁₅NO₇
• 分子量: 309.276
• InChiKey: LWHWPIHFMAOQQQ-AMSAUXSNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-deoxy-2-phthalimido-D-glucopyranose 在 吡啶 、 甲醇 、 三氟化硼乙醚 、 sodium methylate 、 乙二胺 作用下， 以 乙醇 、 氯仿 、 甲苯 为溶剂， 生成 ethyl 2-amino-2-deoxy-1-thio-β-D-glucopyranoside
  参考文献：
  名称：

  Design and synthesis of novel cell wall inhibitors of Mycobacterium tuberculosis GlmM and GlmU

  摘要：

  GlmM and GlmU are key enzymes in the biosynthesis of UDP-N-acetyl-D-glucosamine (UDP-GlcNAc), an essential precursor of peptidoglycan and the rhamnose-GlcNAc linker region in the mycobacterial cell wall. These enzymes are involved in the conversion of two important precursors of UDP-GlcNAc, glucosamine-6-phosphate (GlcN-6-P) and glucosamine-1-phosphate (GlcN-1-P). GlmM converts GlcN-6-P to GlcN-1-P, GlmU is a bifunctional enzyme, whereby GlmU converts GlcN-1-P to GlcNAc-1-P and then catalyzes the formation of UDP-GlcNAc from GlcNAc-1-P and uridine triphosphate. In the present study, methyl 2-amino-2-deoxyl-alpha-D-glucopyranoside 6-phosphate (1 alpha), methyl 2-amino-2deoxyl-beta-D-glucopyranoside 6-phosphate (1 beta), two analogs of GlcN-6-P, were synthesized as GlmM inhibitors; 2-azido-2-deoxy-alpha-D-glucopyranosyl phosphate (2) and 2-amino-2,3-dideoxy-3-fluoro-alpha-Dglucopyranosyl phosphate (3), analogs of GlcN-1-P, were synthesized firstly as GlmU inhibitors. Compounds 1 alpha, 1 beta, 2, and 3 as possible inhibitors of mycobacterial GlmM and GlmU are reported herein. Compound 3 showed promising inhibitory activities against GlmU, whereas 1 beta, 1 beta and 2 were inactive against GlmM and GlmU even at high concentrations. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2011.05.024
• 作为产物：
  描述：

  苯酐 、 D-氨基葡萄糖盐酸盐 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 9.0h， 生成 2-deoxy-2-phthalimido-D-glucopyranose
  参考文献：
  名称：

  Synthesis of oligonucleotides with glucosamine at the 3′-position and evaluation of their biological activity

  摘要：

  Short interfering RNA (siRNA) has been proven to be an utilizable tool for post-transcriptional gene silencing research. In this study, we designed and synthesized two glucosamine analogues and tried to modify the siRNA using these two glucosamine analogues at the 3'-overhang region of siRNAs to improve the nuclease resistance and to overcome some other weak points. The siRNAs modified with glucosamine analogues had almost no effect of the thermal stability and showed strong resistance to nuclease degradation. Some of them kept the same gene silencing activity level as unmodified siRNA. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.036

文献信息

• [EN] CARBOHYDRATE-MODIFIED GLYCOPROTEINS AND USES THEREOF<br/>[FR] GLYCOPROTÉINES MODIFIÉES PAR GLUCIDE ET LEURS UTILISATIONS
  申请人：NEWLINK GENETICS CORP

  公开号：WO2014151423A1

  公开（公告）日：2014-09-25

  The present invention provides immunogenic compounds which stimulate immune responses in a subject. The present invention provides compositions comprising an isolated glycoprotein antigen covalently bound at pre-existing carbohydrate residues present on the glycoprotein to a carbohydrate epitope. The present invention also provides a method to induce an immune response in a subject comprising administering the compounds of the invention. The present invention further provides methods of making the compounds of the invention and methods of using the compounds of the invention to stimulate immune responses to infectious disease agents and tumors.

  本发明提供了刺激受试者免疫反应的免疫原化合物。本发明提供了包含一个孤立的糖蛋白抗原的组合物，该糖蛋白抗原以共价结合的方式结合在糖蛋白上已有的糖残基上，形成一个糖基表位。本发明还提供了一种诱导受试者免疫反应的方法，包括给予本发明的化合物。本发明还提供了制备本发明化合物的方法，以及利用本发明化合物刺激免疫反应以应对传染病和肿瘤的方法。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2018006063A1

  公开（公告）日：2018-01-04

  Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides conjugated to one or more monosaccharide or oligosaccharide moieties. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

  用于治疗细菌感染的组合物和方法包括含有环七肽二聚体与一个或多个单糖或寡糖基团结合的化合物。特别是，这些化合物可用于治疗由革兰氏阴性细菌引起的细菌感染。
• A Generalized Procedure for the One-Pot Preparation of Glycosyl Azides and Thioglycosides Directly from Unprotected Reducing Sugars under Phase-Transfer Reaction Conditions
  作者：Rishi Kumar、Pallavi Tiwari、Prakas R. Maulik、Anup K. Misra

  DOI：10.1002/ejoc.200500646

  日期：2006.1

  Per-O-acetylated glycosyl azides and thioglycosides were prepared in excellent yield directly from unprotected reducing sugars through in situ generation of per-O-acetylated glycosyl bromides by a generalized one-pot procedure under phase-transfer conditions. Stereoselective products were formed with complete inversion at the anomeric centers of the glycosyl bromides to provide a general high-yielding

  过氧乙酰化糖基叠氮化物和硫代糖苷直接从未保护的还原糖通过通用的一锅法在相转移条件下原位生成过氧乙酰化糖基溴化物，以优异的收率制备。在糖基溴化物的异头中心完全反转形成立体选择性产物，为制备 1,2-反式糖基叠氮化物和硫代糖苷提供了一种通用的高产率方法。（© Wiley-VCH Verlag GmbH & Co. KGaA， 69451 德国魏因海姆，2006）
• [EN] BIFUNCTIONAL COMPOUND AND ITS USE IN IMMUNOTHERAPY<br/>[FR] COMPOSÉ BIFONCTIONNEL ET SON UTILISATION EN IMMUNOTHÉRAPIE
  申请人：CONSEJO SUPERIOR INVESTIGACION

  公开号：WO2021023512A1

  公开（公告）日：2021-02-11

  The invention relates to a bifunctional compound that is, on one side, an agonist of the TLR4 and, on the other side, an important inhibitor of the PSMA. Said compound is useful in immunotherapy for the treatment and/or prevention of prostate cancer. Therefore, the invention also relates to the use of the compound and to the pharmaceutical composition comprising it.

  这项发明涉及一种双功能化合物，一方面是TLR4的激动剂，另一方面是PSMA的重要抑制剂。该化合物在免疫疗法中用于治疗和/或预防前列腺癌。因此，该发明还涉及该化合物的使用以及包含该化合物的药物组合物。
• Synthesis and characterization of N-acyl-tetra-O-acyl glucosamine derivatives
  作者：Chi-Hien Dang、Cong-Hao Nguyen、Thanh-Danh Nguyen、Chan Im

  DOI：10.1039/c3ra46007j

  日期：——

  Novel 1,3,4,6-tetra-O-acyl-N-acyl-D-glucosamine derivatives were synthesized from glucosamine hydrochloride (GlcN·HCl) by the acylation with pyridine as a catalyst. A derivative of tetra-O-acetyl glucosamine contained ketoprofen, a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic effects, was first synthesized. In analysis of the NMR spectra, the ratio of α:β-anomer showed that penta-acyl-D-glucosamine derivatives and N-acetylated glucosamines containing O-acyl groups have been only the α-anomer. Meanwhile, both the intermediates and the glucoconjugate compound of ketoprofen have only the β-anomer.

  利用吡啶作为催化剂，通过酰化反应从葡萄糖胺盐酸盐（GlcN·HCl）合成了新型1,3,4,6-四-O-酰基-N-酰基-D-葡萄糖胺衍生物。首次合成了一种含有酮洛芬的四-O-乙酰基葡萄糖胺衍生物，酮洛芬是一种具有镇痛和退热作用的无菌性抗炎药物（NSAID）。通过NMR谱图分析，α:β-异构体的比例表明，含有O-酰基的五酰基-D-葡萄糖胺衍生物和N-乙酰化的葡萄糖胺均为α-异构体。同时，酮洛芬的中间体和葡萄糖结合物均为β-异构体。